Needham analyst Chad Messer raised his price target on Esperion to $94 and kept his Strong Buy rating. Messer notes that regulatory uncertainty for the company is in the past, while the phase 3 readouts on its Bempedoic Acid products starting next month could disclose further progress toward a "blockbuster opportunity". The analyst says that the readouts are "significantly de-risked" given the lack of any safety signals to date.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here